Stryker (SYK) Q1 2026 Earnings Transcript

Stryker reported Q1 adjusted EPS of $2.60, down 8.5% year over year, and organic sales growth of 2.4%, with results materially disrupted by a late-quarter cyber incident that cut gross margin 190 bps to 63.6% and operating margin 180 bps to 21.1%. Despite the setback, management reaffirmed full-year 2026 guidance for 8%-9.5% organic sales growth and $14.90-$15.10 adjusted EPS, citing expected recovery in Q2-Q4, strong hospital demand, and an elevated capital order book. The company also highlighted record Mako installations, new product approvals, and the announced Amplitude Vascular Systems acquisition, which supports its continued M&A strategy.

Analysis

The market is likely underestimating how much of this quarter’s weakness is simply timing noise versus true demand impairment. The operational shock hit the most financialized parts of the model first — capital equipment, make-to-order, and revenue recognition-heavy channels — which means the near-term P&L looks worse than the underlying procedure trend, but it also creates a mechanically stronger back-half setup as shipments, installs, and deferred cases all stack into Q3/Q4.

The bigger second-order effect is competitive. If Stryker can restore service levels quickly and maintain its order book, the incident may actually strengthen share with hospital customers who value continuity and field support; meanwhile, smaller peers with thinner manufacturing redundancy are more exposed to any supply-chain hiccup. The Orthotech restructuring also matters because it tightens the sell-through loop between robotics, instruments, and consumables, improving cross-sell economics and making the orthopedic franchise harder to dislodge even if competitors get more aggressive on salesforce reshuffling.

From a catalyst standpoint, the next 60-120 days are less about beating the quarter and more about proving the revenue catch-up is real. If Q2 shows only partial normalization, the stock can de-rate on fears of permanent case loss or lingering operational friction; if management starts to surface accelerating back-half order conversion, the multiple should re-rate quickly because the guidance reset risk is low. The true contrarian point: this may be one of the rare instances where a cyber event leaves the moat wider, not narrower, by forcing customers to revalidate Stryker as a mission-critical vendor.

Key Decisions for Investors

• Long SYK on a 3-6 month horizon into expected Q2/Q3 recovery; use weakness tied to cyber headlines as entry, targeting a re-rating as deferred revenue and rescheduled procedures normalize. Risk/reward is favorable if the market is discounting permanent demand loss that management says is not occurring.
• Add to SYK vs. short a basket of smaller-cap medtech names with higher supply-chain fragility (pair trade) to express relative resilience; thesis is that Stryker’s recovery and customer trust may come out stronger while peers remain more operationally exposed.
• Buy SYK call spreads expiring after Q3 earnings to capture the back-half catch-up without paying full premium for unlimited upside; this is best if management confirms shipment recovery and no erosion in capital order book.
• Fade any post-earnings margin panic in SYK unless there is evidence of true demand decay; the quarter’s margin pressure looks transitory and should normalize faster than consensus expects if production and revenue recognition fully reset.
• Watch for a tactical long in industrial/cyber remediation beneficiaries only if more healthcare vendor incidents emerge; otherwise, SYK itself is the cleaner trade because the event appears more idiosyncratic than systemic.